Get the Stockscreener App
24.52
3.69%
-0.94
Pre-market:
25.05
0.53
+2.16%
Intellia Therapeutics Inc stock is traded at $24.52, with a volume of 8.50M.
It is down -3.69% in the last 24 hours and up +117.18% over the past month.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
See More
Previous Close:
$25.46
Open:
$25.62
24h Volume:
8.50M
Relative Volume:
1.56
Market Cap:
$2.63B
Revenue:
$45.97M
Net Income/Loss:
$-508.80M
P/E Ratio:
-4.4745
EPS:
-5.48
Net Cash Flow:
$-382.65M
1W Performance:
+22.85%
1M Performance:
+117.18%
6M Performance:
+262.19%
1Y Performance:
+37.83%
1-Day Range:
$23.22
$25.78
1-Week Range:
$19.89
$26.98
52-Week Range:
$5.90
$26.98
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Name
Intellia Therapeutics Inc
Sector
Industry
Phone
857-285-6200
Address
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
24.52 | 2.73B | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-21-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-05-25 | Initiated | H.C. Wainwright | Buy |
| Feb-28-25 | Downgrade | Goldman | Neutral → Sell |
| Feb-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-27-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-23-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Mar-14-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-19-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Sell |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Jun-16-22 | Initiated | BofA Securities | Buy |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Feb-18-22 | Initiated | William Blair | Outperform |
| Feb-07-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-22 | Initiated | Cowen | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
| Oct-05-21 | Initiated | Guggenheim | Buy |
| Sep-24-21 | Initiated | Stifel | Buy |
| Jun-28-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-11-21 | Initiated | H.C. Wainwright | Buy |
| May-07-21 | Upgrade | ROTH Capital | Neutral → Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-22-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-27-20 | Initiated | Truist | Buy |
| Oct-14-20 | Initiated | Wells Fargo | Overweight |
| Sep-18-20 | Initiated | Goldman | Buy |
| Feb-28-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-14-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-01-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-09-19 | Initiated | Robert W. Baird | Outperform |
| Jun-10-19 | Initiated | ROTH Capital | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Nov-02-18 | Downgrade | Wedbush | Outperform → Neutral |
| Oct-29-18 | Initiated | Credit Suisse | Neutral |
| Sep-21-18 | Initiated | Raymond James | Mkt Perform |
| May-15-18 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-08-18 | Initiated | JMP Securities | Mkt Outperform |
| Nov-01-17 | Reiterated | Jefferies | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-05-16 | Upgrade | Jefferies | Hold → Buy |
View All
Intellia Therapeutics Inc Stock (NTLA) Latest News
What Recent Gene Editing Breakthroughs Mean for the Future of Intellia Therapeutics Stock - Yahoo Finance
Why Intellia Therapeutics (NTLA) Is Up 22.8% After Promising Gene-Editing Data at ESGCT 2025 and Phase 3 Enrollment - Yahoo Finance
A Look at Intellia Therapeutics’s Valuation Following Breakthrough ATTR Data and HAELO Study Milestone - Yahoo Finance
Published on: 2025-10-12 05:21:21 - newser.com
Cyndeo Wealth Partners LLC Invests $101,000 in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Intellia Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Will Intellia Therapeutics Inc. (38I) stock profit from automation wave2025 Fundamental Recap & AI Driven Stock Reports - newser.com
CRISPR Market Size, Share, Recent Developments, Growth - openPR.com
Using flow based indicators on Intellia Therapeutics Inc.Weekly Stock Analysis & Community Consensus Picks - newser.com
Intellia Therapeutics Hits New 52-Week High at $26.45 - Markets Mojo
Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6% - MSN
Intellia Therapeutics Stock Soars on Gene-Editing Breakthrough – Analysts Eye 70–100% Upside - ts2.tech
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock? - Yahoo Finance
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - Yahoo Finance
Intellia Therapeutics' (NTLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Can Intellia Therapeutics Inc. (38I) stock test all time highsM&A Rumor & Safe Entry Point Identification - newser.com
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know - sharewise.com
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook - ts2.tech
Is Intellia Therapeutics Inc 38I a good long term investmentRetail Investor Activity & Actionable Entry & Exit Points Daily - earlytimes.in
Intellia Therapeutics (NASDAQ:NTLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Intellia Therapeutics (NTLA) Surges Over 23% in Market Trading - GuruFocus
On Course: Intellia CSO Offers Clinical Update of In Vivo Gene Editing Therapies at ESGCT - Genetic Engineering and Biotechnology News
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - AOL.com
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should Know - Yahoo Finance
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Supercharged Gene-Editing: Intellia’s 63% Rally Just The Start, Say Analysts - NAI500
Intellia Therapeutics Inc Stock Analysis and ForecastBear Market Strategies & Easy Tools to Analyze Your Investment Risk - earlytimes.in
1 Stock Up by 63% This Year That Could Double, According to Wall Street - Yahoo Finance
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Intellia Therapeutics stock hits 52-week high at 21.49 USD By Investing.com - Investing.com Canada
Intellia Therapeutics (NTLA) Sees Stock Rise Following Analyst U - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year High on Analyst Upgrade - MarketBeat
Intellia Therapeutics stock hits 52-week high at 21.49 USD - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Upgraded by JMP Securities to Market Outperform Rating - MarketBeat
JMP Securities Upgrades Intellia Therapeutics (NTLA) - Nasdaq
What Analysts Are Saying About Intellia Therapeutics Stock - Benzinga
Intellia Therapeutics (NTLA) Upgraded by JMP Securities to Marke - GuruFocus
Published on: 2025-10-06 06:23:31 - newser.com
Intellia Therapeutics (NTLA) Sees Strong Gains as Ark Invest Inc - GuruFocus
Cathie Wood's Ark Invest weekly recap: adds more Alibaba, Baidu, Kodiak AI, Intellia to its funds (ARKK:BATS) - Seeking Alpha
How Intellia Therapeutics Inc. (38I) stock performs in easing cyclesQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Citizens upgrades Intellia Therapeutics stock rating on strong HAE outlook - Investing.com
How Intellia Therapeutics Inc. stock reacts to global recession fearsQuarterly Risk Review & Free Expert Verified Stock Movement Alerts - newser.com
Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details - MSN
Intellia Therapeutics shares up after Wolfe upgrade - MSN
Cathie Wood Goes Shopping: 3 Rising Stocks She Just Bought - AOL.com
Intellia Therapeutics (NTLA) Is Up 22.4% After Promising Phase 1 Data and ARK Investment Buy-In—What's Changed - Sahm
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Executive Makes Notable Stock Sale - TipRanks
Intellia Therapeutics (NASDAQ:NTLA) CAO Sells $32,517.98 in Stock - MarketBeat
Intellia Therapeutics Inc Stock (NTLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intellia Therapeutics Inc Stock (NTLA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dube Michael P | VP, Chief Accounting Officer |
Oct 01 '25 |
Sale |
17.38 |
1,871 |
32,518 |
55,266 |
| CHASE WILLIAM J | Director |
Aug 20 '25 |
Buy |
10.03 |
100,000 |
1,003,000 |
134,693 |
| Dulac Edward J III | EVP, Chief Financial Officer |
Jul 23 '25 |
Sale |
14.02 |
7,462 |
104,617 |
106,062 |
| Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '25 |
Sale |
9.82 |
1,022 |
10,036 |
95,369 |
| Dube Michael P | VP, Chief Accounting Officer |
Jul 02 '25 |
Sale |
9.95 |
2,503 |
24,905 |
57,137 |
| GOODMAN JESSE | Director |
Jun 30 '25 |
Sale |
9.56 |
1,547 |
14,789 |
25,906 |
| GOODMAN JESSE | Director |
Jul 01 '25 |
Sale |
9.23 |
1,547 |
14,279 |
24,359 |
| Bhanji Muna | Director |
Apr 29 '25 |
Sale |
8.50 |
265 |
2,252 |
19,203 |
| Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '25 |
Sale |
8.99 |
679 |
6,104 |
95,369 |
| BASTA JAMES | EVP, General Counsel |
Mar 04 '25 |
Sale |
8.99 |
2,572 |
23,122 |
111,925 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):